The present invention relates to a process for the selective reduction of cysteine-engineered antibodies comprising reacting an antibody comprising one or more engineered cysteines at positions selected from HC40, HC41,HC42, HC89, HC152, HC153, HC155, HC171, LC40, LC41, LC165, and LC168 with a compound according to formula (I), (II), (III), (IV), (V), (VI) or (VII): (I) (II) (III) (IV) (V) (VI) (VII), and to a process for the preparation of antibody conjugates, including antibody-drug conjugates (ADCs).
本发明涉及一种选择性还原半胱
氨酸工程化
抗体的工艺,包括将在选自 HC40、HC41、HC42、HC89、HC152、HC153、HC155、HC171、LC40、LC41、LC165 和 LC168 的位置上包含一个或多个工程化半胱
氨酸的
抗体与根据式(I)、(II)、(III)、(IV)、(V)、(VI)或(VII)的化合物反应:(I)(II)(III)(IV)(V)(VI)(VII)的化合物,以及制备
抗体共轭物,包括
抗体-药物共轭物(ADC)的工艺。